NEOD001: The VITAL Amyloidosis Study

NEOD001 in amyloidosisПодробнее

NEOD001 and AL AmyloidosisПодробнее

Promising Cardiac and Renal Responses with NEOD001 in Patients with AL AmyloidosisПодробнее

Cardiac Amyloidosis - NEOD001 Mayo Clinic Rochester, MN - Dan LierПодробнее

Birtamimab (NEOD001): changing the treatment of amyloidosisПодробнее

VITAL results for birtamimab in AL amyloidosisПодробнее

NEOD001 and AL AmyloidosisПодробнее

AL AmyloidosisПодробнее

Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosisПодробнее

Real-world management of patients with AL amyloidosisПодробнее

Amyloid light chain (AL) amyloidosis | cardiac amyloidosis | amyloid deposits #medicalanimationПодробнее

Amyloidosis and Peripheral NeuropathyПодробнее

Chemotherapy-free approaches to AL amyloidosisПодробнее

Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvementПодробнее

Survival Benefit of Birtamimab in Treating AL AmyloidosisПодробнее

DOCTORS of AmyloidosisПодробнее

Andrew Cowan, MD - Diagnosis and Treatment of AL Amyloidosis in 2020Подробнее

Amyloidosis Studies at Takeda OncologyПодробнее

New antibody treatments for AL amyloidosisПодробнее